AAVogen
AAvogen is a preclinical-stage biotech that develops gene therapeutics for rare muscle-wasting diseases, including muscular dystrophies and myopathies. Novel viral vectors de-targeted for the liver but with enhanced muscle tropism are also being developed for superior safety.
Contact Name:
Dan Rodgers
Contact Email:
Website:
http://aavogen.com
City, State – Congressional District:
Rockville,
MD
–
8
Technology:
Drug
Funding:
Aging (NIA),
Arthritis, Musculoskeletal, and Skin (NIAMS),
Cancer (NCI)
NIH Projects:
NIH RePorter for
AAVogen
Sponsored Event(s):
BIO | 2024
,
Landmark Investing for Cures | 2020
